vs
Alexander & Baldwin, Inc.（ALEX）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
Alexander & Baldwin, Inc.的季度营收约是RECURSION PHARMACEUTICALS, INC.的1.4倍（$51.0M vs $35.5M），Alexander & Baldwin, Inc.净利率更高（7.4% vs -304.2%，领先311.6%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs -18.4%），Alexander & Baldwin, Inc.自由现金流更多（$27.3M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs -8.7%）
亚历山大-鲍德温公司是一家美国企业，曾是夏威夷领地时期五大财团之一，也是五大财团中最晚停止甘蔗种植的企业。目前公司主营房地产开发、土地运营以及建材与建筑业务，截至2020年，该公司是夏威夷最大的私人土地持有者之一，在当地拥有超2.8万英亩土地，运营着36处收益性物业。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
ALEX vs RXRX — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $51.0M | $35.5M |
| 净利润 | $3.8M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | 17.1% | -304.8% |
| 净利率 | 7.4% | -304.2% |
| 营收同比 | -18.4% | 681.7% |
| 净利润同比 | -69.7% | 39.6% |
| 每股收益（稀释后） | $0.05 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $51.0M | $35.5M | ||
| Q3 25 | $50.2M | $5.2M | ||
| Q2 25 | $51.7M | $19.2M | ||
| Q1 25 | $53.7M | $14.7M | ||
| Q4 24 | $62.4M | $4.5M | ||
| Q3 24 | $61.9M | $26.1M | ||
| Q2 24 | $51.0M | $14.4M | ||
| Q1 24 | $61.2M | $13.8M |
| Q4 25 | $3.8M | $-108.1M | ||
| Q3 25 | $14.3M | $-162.3M | ||
| Q2 25 | $25.1M | $-171.9M | ||
| Q1 25 | $21.4M | $-202.5M | ||
| Q4 24 | $12.4M | $-178.9M | ||
| Q3 24 | $19.0M | $-95.8M | ||
| Q2 24 | $9.1M | $-97.5M | ||
| Q1 24 | $20.0M | $-91.4M |
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
| Q4 25 | 17.1% | -304.8% | ||
| Q3 25 | 38.2% | -3327.6% | ||
| Q2 25 | 54.4% | -916.8% | ||
| Q1 25 | 44.6% | -1297.9% | ||
| Q4 24 | 28.3% | -4042.4% | ||
| Q3 24 | 35.6% | -377.1% | ||
| Q2 24 | 31.8% | -697.4% | ||
| Q1 24 | 38.9% | -698.4% |
| Q4 25 | 7.4% | -304.2% | ||
| Q3 25 | 28.5% | -3135.3% | ||
| Q2 25 | 48.6% | -894.2% | ||
| Q1 25 | 39.9% | -1373.3% | ||
| Q4 24 | 19.9% | -3935.5% | ||
| Q3 24 | 30.7% | -367.5% | ||
| Q2 24 | 17.8% | -676.6% | ||
| Q1 24 | 32.6% | -662.4% |
| Q4 25 | $0.05 | $-0.17 | ||
| Q3 25 | $0.20 | $-0.36 | ||
| Q2 25 | $0.35 | $-0.41 | ||
| Q1 25 | $0.29 | $-0.50 | ||
| Q4 24 | $0.16 | $-0.56 | ||
| Q3 24 | $0.26 | $-0.34 | ||
| Q2 24 | $0.13 | $-0.40 | ||
| Q1 24 | $0.28 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $11.3M | $743.3M |
| 总债务越低越好 | $491.6M | $9.6M |
| 股东权益账面价值 | $987.2M | $1.1B |
| 总资产 | $1.7B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.50× | 0.01× |
8季度趋势，按日历期对齐
| Q4 25 | $11.3M | $743.3M | ||
| Q3 25 | $17.3M | $659.8M | ||
| Q2 25 | $8.6M | $525.1M | ||
| Q1 25 | $16.9M | $500.5M | ||
| Q4 24 | $33.4M | $594.4M | ||
| Q3 24 | $17.9M | $427.6M | ||
| Q2 24 | $29.5M | $474.3M | ||
| Q1 24 | $15.7M | $296.3M |
| Q4 25 | $491.6M | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | $474.8M | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
| Q4 25 | $987.2M | $1.1B | ||
| Q3 25 | $1.0B | $1.0B | ||
| Q2 25 | $1.0B | $919.1M | ||
| Q1 25 | $1.0B | $933.9M | ||
| Q4 24 | $1.0B | $1.0B | ||
| Q3 24 | $998.2M | $524.6M | ||
| Q2 24 | $1.0B | $584.4M | ||
| Q1 24 | $1.0B | $401.2M |
| Q4 25 | $1.7B | $1.5B | ||
| Q3 25 | $1.7B | $1.4B | ||
| Q2 25 | $1.6B | $1.3B | ||
| Q1 25 | $1.6B | $1.3B | ||
| Q4 24 | $1.7B | $1.4B | ||
| Q3 24 | $1.7B | $726.5M | ||
| Q2 24 | $1.6B | $775.9M | ||
| Q1 24 | $1.6B | $557.8M |
| Q4 25 | 0.50× | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | 0.47× | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $79.5M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $27.3M | $-47.3M |
| 自由现金流率自由现金流/营收 | 53.5% | -133.1% |
| 资本支出强度资本支出/营收 | 102.4% | 3.5% |
| 现金转化率经营现金流/净利润 | 21.06× | — |
| 过去12个月自由现金流最近4个季度 | $57.2M | $-378.3M |
8季度趋势，按日历期对齐
| Q4 25 | $79.5M | $-46.1M | ||
| Q3 25 | $24.5M | $-117.4M | ||
| Q2 25 | $16.5M | $-76.4M | ||
| Q1 25 | $26.0M | $-132.0M | ||
| Q4 24 | $98.0M | $-115.4M | ||
| Q3 24 | $35.3M | $-59.2M | ||
| Q2 24 | $22.3M | $-82.2M | ||
| Q1 24 | $16.1M | $-102.3M |
| Q4 25 | $27.3M | $-47.3M | ||
| Q3 25 | $-3.7M | $-117.6M | ||
| Q2 25 | $11.8M | $-79.6M | ||
| Q1 25 | $21.8M | $-133.8M | ||
| Q4 24 | $77.0M | $-116.7M | ||
| Q3 24 | $31.4M | $-63.8M | ||
| Q2 24 | $18.0M | $-83.4M | ||
| Q1 24 | $12.3M | $-109.0M |
| Q4 25 | 53.5% | -133.1% | ||
| Q3 25 | -7.4% | -2272.5% | ||
| Q2 25 | 22.8% | -413.9% | ||
| Q1 25 | 40.6% | -907.4% | ||
| Q4 24 | 123.4% | -2567.7% | ||
| Q3 24 | 50.8% | -244.6% | ||
| Q2 24 | 35.3% | -578.5% | ||
| Q1 24 | 20.1% | -789.9% |
| Q4 25 | 102.4% | 3.5% | ||
| Q3 25 | 56.1% | 4.7% | ||
| Q2 25 | 9.1% | 16.4% | ||
| Q1 25 | 7.8% | 12.4% | ||
| Q4 24 | 33.5% | 28.6% | ||
| Q3 24 | 6.2% | 17.5% | ||
| Q2 24 | 8.4% | 8.2% | ||
| Q1 24 | 6.1% | 48.2% |
| Q4 25 | 21.06× | — | ||
| Q3 25 | 1.71× | — | ||
| Q2 25 | 0.66× | — | ||
| Q1 25 | 1.21× | — | ||
| Q4 24 | 7.88× | — | ||
| Q3 24 | 1.86× | — | ||
| Q2 24 | 2.45× | — | ||
| Q1 24 | 0.80× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
